nimodipine has been researched along with Acute Confusional Senile Dementia in 38 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of galantamine (GAL) on quality of life (QoL) and cognitive speed, as well its effects combined with nimodipine (NIM) in Alzheimer disease (AD) with cerebrovascular disease (mixed dementia), have not been explored." | 9.19 | Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study). ( Barbosa, MT; Bottino, CM; Caramelli, P; Charchat-Fichman, H; Chaves, ML; Forlenza, OV; Laks, J; Lawson, FL; Machado, JC; Nitrini, R; Palmini, AL; Vale, Fde A, 2014) |
| " In a multicenter, placebo-controlled, double-blind clinical study in 178 elderly patients with cognitive decline, nimodipine, a calcium antagonist was found to be a therapeutically effective agent in the treatment of old age dementias." | 9.06 | Nimodipine in the treatment of old age dementias. ( Aguglia, E; Azzarelli, O; Balsano, F; Ban, TA; Caglieris, N; Capurso, A; Marigliano, V; Morey, L; Sterlicchio, M; Tomasi, NA, 1990) |
| "The effects of galantamine (GAL) on quality of life (QoL) and cognitive speed, as well its effects combined with nimodipine (NIM) in Alzheimer disease (AD) with cerebrovascular disease (mixed dementia), have not been explored." | 5.19 | Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study). ( Barbosa, MT; Bottino, CM; Caramelli, P; Charchat-Fichman, H; Chaves, ML; Forlenza, OV; Laks, J; Lawson, FL; Machado, JC; Nitrini, R; Palmini, AL; Vale, Fde A, 2014) |
| " In a multicenter, placebo-controlled, double-blind clinical study in 178 elderly patients with cognitive decline, nimodipine, a calcium antagonist was found to be a therapeutically effective agent in the treatment of old age dementias." | 5.06 | Nimodipine in the treatment of old age dementias. ( Aguglia, E; Azzarelli, O; Balsano, F; Ban, TA; Caglieris, N; Capurso, A; Marigliano, V; Morey, L; Sterlicchio, M; Tomasi, NA, 1990) |
| " Therefore, meta-analysis is employed in this study to evaluate the efficacy and safety of using donepezil hydrochloride combined with nimodipine in treating VaD to provide references for clinical treatments." | 2.82 | A systematic review of the efficacy of donepezil hydrochloride combined with nimodipine on treating vascular dementia. ( Huang, KL; Liu, J; Ran, SM; Tan, AH; Wang, GY; Wang, MY; Yang, Q, 2022) |
| "Nimodipine is an isopropyl calcium channel blocker which readily crosses the blood-brain barrier." | 2.41 | Nimodipine for primary degenerative, mixed and vascular dementia. ( Birks, J; López-Arrieta, JM, 2002) |
| "Nimodipine is an isopropyl calcium channel blocker which can easily cross the blood brain barrier." | 2.41 | Nimodipine for primary degenerative, mixed and vascular dementia. ( Birks, J; López-Arrieta, JM, 2000) |
| "Nimodipine is an isopropyl calcium channel blocker which can easily cross the blood brain barrier." | 2.41 | Nimodipine for primary degenerative, mixed and vascular dementia. ( Birks, J, 2001) |
| "Nimodipine is a calcium antagonist which improves learning and memory in brain-lesioned or aged animals (LeVere & Sandin, 1989; Schuurman & Traber, 1989)." | 2.38 | Global rating, symptoms, behavior, and cognitive performance as indicators of efficacy in clinical studies with nimodipine in elderly patients with cognitive impairment syndromes. ( Bergener, M; Schmage, N, 1992) |
| "Nimodipine was well tolerated and crossed the blood brain barrier, as expected, but there was no effect on Aβ accumulation or on the relative amount of neuritic dystrophy, as assessed by either immunoblot, dot blot or immunofluorescence imaging of Aβ42 and dystrophic neurite marker LAMP1." | 1.72 | Oral nimodipine treatment has no effect on amyloid pathology or neuritic dystrophy in the 5XFAD mouse model of amyloidosis. ( Khatri, A; Popovic, J; Sadleir, KR; Vassar, R, 2022) |
| "Nimodipine has received attention as a drug that might improve learning and reduce cognitive deficits in Alzheimer's disease, but the mechanism of action is poorly known." | 1.38 | Nimodipine inhibits IL-1β release stimulated by amyloid β from microglia. ( Chiozzi, P; Colaianna, M; Di Virgilio, F; Ferrari, D; Sanz, JM; Trabace, L; Zotti, M; Zuliani, G, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (36.84) | 18.2507 |
| 2000's | 11 (28.95) | 29.6817 |
| 2010's | 9 (23.68) | 24.3611 |
| 2020's | 4 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Marco-Contelles, J | 5 |
| León, R | 3 |
| de Los Ríos, C | 3 |
| Guglietta, A | 1 |
| Terencio, J | 1 |
| López, MG | 3 |
| García, AG | 3 |
| Villarroya, M | 3 |
| Samadi, A | 1 |
| Bartolini, M | 2 |
| Andrisano, V | 1 |
| Huertas, O | 1 |
| Barril, X | 1 |
| Luque, FJ | 1 |
| Rodríguez-Franco, MI | 2 |
| López, B | 2 |
| Carreiras, Mdo C | 1 |
| González-Muñoz, GC | 1 |
| Arce, MP | 1 |
| Pérez, C | 1 |
| Romero, A | 1 |
| del Barrio, L | 1 |
| Martín-de-Saavedra, MD | 1 |
| Egea, J | 1 |
| Conde, S | 1 |
| Chioua, M | 1 |
| Buzzi, E | 1 |
| Moraleda, I | 2 |
| Iriepa, I | 2 |
| Maj, M | 3 |
| Wnorowski, A | 3 |
| Giovannini, C | 1 |
| Tramarin, A | 1 |
| Portali, F | 1 |
| Ismaili, L | 3 |
| López-Alvarado, P | 1 |
| Bolognesi, ML | 1 |
| Jóźwiak, K | 3 |
| Menéndez, JC | 1 |
| Bisi, A | 1 |
| Arribas, RL | 1 |
| Micucci, M | 1 |
| Budriesi, R | 1 |
| Feoli, A | 1 |
| Castellano, S | 1 |
| Belluti, F | 1 |
| Gobbi, S | 1 |
| Rampa, A | 1 |
| Sadleir, KR | 1 |
| Popovic, J | 1 |
| Khatri, A | 1 |
| Vassar, R | 1 |
| Yang, Q | 1 |
| Liu, J | 1 |
| Huang, KL | 1 |
| Wang, GY | 1 |
| Wang, MY | 1 |
| Tan, AH | 1 |
| Ran, SM | 1 |
| Zheng, Z | 1 |
| Wu, K | 1 |
| Ruan, Q | 1 |
| Li, D | 1 |
| Liu, W | 1 |
| Wang, M | 1 |
| Li, Y | 1 |
| Xia, J | 1 |
| Yang, D | 1 |
| Guo, J | 1 |
| Malek, R | 1 |
| Martin, H | 2 |
| Chabchoub, F | 1 |
| Pachòn Angona, I | 1 |
| Daniel, S | 1 |
| Bonet, A | 1 |
| Silva, TB | 1 |
| Refouvelet, B | 1 |
| Borges, F | 1 |
| Lozupone, M | 1 |
| La Montagna, M | 1 |
| D'Urso, F | 1 |
| Piccininni, C | 1 |
| Sardone, R | 1 |
| Dibello, V | 1 |
| Giannelli, G | 1 |
| Solfrizzi, V | 1 |
| Greco, A | 1 |
| Daniele, A | 1 |
| Quaranta, N | 1 |
| Seripa, D | 1 |
| Bellomo, A | 1 |
| Logroscino, G | 1 |
| Panza, F | 1 |
| Caramelli, P | 1 |
| Laks, J | 1 |
| Palmini, AL | 1 |
| Nitrini, R | 1 |
| Chaves, ML | 1 |
| Forlenza, OV | 1 |
| Vale, Fde A | 1 |
| Barbosa, MT | 1 |
| Bottino, CM | 1 |
| Machado, JC | 1 |
| Charchat-Fichman, H | 1 |
| Lawson, FL | 1 |
| Gholami Pourbadie, H | 1 |
| Naderi, N | 1 |
| Janahmadi, M | 1 |
| Mehranfard, N | 1 |
| Motamedi, F | 1 |
| Ito, K | 1 |
| Kato, T | 1 |
| Barua, NU | 1 |
| Miners, JS | 1 |
| Bienemann, AS | 1 |
| Wyatt, MJ | 1 |
| Welser, K | 1 |
| Tabor, AB | 1 |
| Hailes, HC | 1 |
| Love, S | 1 |
| Gill, SS | 1 |
| Sanz, JM | 1 |
| Chiozzi, P | 1 |
| Colaianna, M | 1 |
| Zotti, M | 1 |
| Ferrari, D | 1 |
| Trabace, L | 1 |
| Zuliani, G | 1 |
| Di Virgilio, F | 1 |
| López-Arrieta, JM | 2 |
| Birks, J | 3 |
| Kohler, J | 1 |
| Riepe, MW | 1 |
| Jendroska, K | 1 |
| Pilartz, H | 1 |
| Adler, G | 1 |
| Berger, FM | 1 |
| Calabrese, P | 1 |
| Frölich, L | 1 |
| Gertz, HJ | 1 |
| Hampel, H | 1 |
| Haupt, M | 1 |
| Mielke, R | 1 |
| Paulus, HJ | 1 |
| Zedlick, D | 1 |
| Matsuzaki, K | 1 |
| Yanagisawa, K | 1 |
| Eckert, A | 1 |
| Piwnica-Worms, D | 1 |
| Kesarwala, AH | 1 |
| Pichler, A | 1 |
| Prior, JL | 1 |
| Sharma, V | 1 |
| Li, N | 1 |
| Liu, B | 1 |
| Dluzen, DE | 1 |
| Jin, Y | 1 |
| Davidson, RM | 1 |
| Shajenko, L | 1 |
| Donta, TS | 1 |
| Disterhoft, JF | 1 |
| Moyer, JR | 1 |
| Thompson, LT | 1 |
| Damulin, IV | 1 |
| Levin, OS | 1 |
| Zakharov, VV | 1 |
| Zhuchenko, TD | 1 |
| Elkin, MN | 1 |
| Fritze, J | 1 |
| Walden, J | 1 |
| Stoppe, G | 1 |
| Sandholzer, H | 1 |
| Staedt, J | 1 |
| Winter, S | 1 |
| Kiefer, J | 1 |
| Rüther, E | 1 |
| Aymard, G | 1 |
| Cayre-Castel, M | 1 |
| Fernandez, C | 1 |
| Lacomblez, L | 1 |
| Diquet, B | 1 |
| Kanowski, S | 1 |
| Grobe-Einsler, R | 1 |
| Traber, J | 1 |
| Schmage, N | 1 |
| Bergener, M | 1 |
| Jarvik, LF | 1 |
| Tollefson, GD | 1 |
| Ban, TA | 1 |
| Morey, L | 1 |
| Aguglia, E | 1 |
| Azzarelli, O | 1 |
| Balsano, F | 1 |
| Marigliano, V | 1 |
| Caglieris, N | 1 |
| Sterlicchio, M | 1 |
| Capurso, A | 1 |
| Tomasi, NA | 1 |
| Möller, HJ | 1 |
| Etienne, P | 1 |
| Hakim, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life[NCT00814658] | Phase 4 | 22 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease[NCT02017340] | Phase 3 | 511 participants (Actual) | Interventional | 2013-04-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The face recognition test is a computerized attention test in which ten unfamiliar faces were presented simultaneously on the computer screen for ten seconds to be remembered. After that, a single face was shown and the patient had to press the button one if he/she remembered or, otherwise, button five. It consisted of a random presentation of ten pre-exposed faces and ten new faces as distracters. The reaction time, assessed per patient, was averaged at each time point for each patient e.g., at baseline, Weeks 8 and 24. This test is part of the Computerized Neuropsychological Test Battery. (NCT00814658)
Timeframe: Baseline, Week 8, Week 24
| Intervention | milliseconds (Mean) |
|---|---|
| Galantamine + Nimodipine (Baseline) | 3124.00 |
| Galantamine + Placebo (Baseline) | 2684.45 |
| Galantamine + Nimodipine (Week 8) | 2262.50 |
| Galantamine + Placebo (Week 8) | 2734.25 |
| Galantamine + Nimodipine (Week 24) | 2357.80 |
| Galantamine + Placebo (Week 24) | 3099.38 |
The Simple Reaction Time is a computerized attention test that evaluates the patient's reaction time. The number one was presented in the center of the computer screen and the patient had to press this number in the response box as quickly as possible. The reaction time, assessed 100 times per patient, was averaged at each time point for each patient e.g., at baseline, Week 8 and Week 24. The patient's finger was put over button one before the test begun. This test is part of the Computerized Neuropsychological Test Battery (CNTB). (NCT00814658)
Timeframe: Baseline, Week 8, Week 24
| Intervention | milliseconds (Mean) |
|---|---|
| Galantamine + Nimodipine (Baseline) | 1024.06 |
| Galantamine + Placebo (Baseline) | 729.18 |
| Galantamine + Nimodipine (Week 8) | 466.60 |
| Galantamine + Placebo (Week 8) | 671.33 |
| Galantamine + Nimodipine (Week 24) | 467.60 |
| Galantamine + Placebo (Week 24) | 584.44 |
The Two-choice reaction time test is a computerized attention test in which the numbers one or five were presented in the center of the computer screen in a random order. The patient had to press the correspondent button in the response box as quickly as possible. The patient's right finger was put over the button five and the left finger over button one before the test begun. The reaction time, assessed 100 times per patient, was averaged at each time point for each patient e.g., at baseline, Week 8 and Week 24.This test is part of the Computerized Neuropsychological Test Battery (CNTB). (NCT00814658)
Timeframe: Baseline, Week 8, Week 24
| Intervention | milliseconds (Mean) |
|---|---|
| Galantamine + Nimodipine (Baseline) | 1919.72 |
| Galantamine + Placebo (Baseline) | 1096.75 |
| Galantamine + Nimodipine (Week 8) | 852.70 |
| Galantamine + Placebo (Week 8) | 1187.78 |
| Galantamine + Nimodipine (Week 24) | 727.60 |
| Galantamine + Placebo (Week 24) | 1116.25 |
The reaction time for word recognition and learning test is a computerized attention test that evaluates the patient's reaction time. This test is similar to the Face Recognition test procedure using Words. The recognition procedure was repeated three times to evaluate a learning effect. The reaction time, assessed per patient, was averaged at each time point for each patient e.g., at baseline, Week 8 and Week 24. This test is part of the Computerized Neuropsychological Test Battery (CNTB). (NCT00814658)
Timeframe: Baseline, Week 8, Week 24
| Intervention | milliseconds (Mean) |
|---|---|
| Galantamine + Nimodipine (Baseline) | 2022.17 |
| Galantamine + Placebo (Baseline) | 2978.77 |
| Galantamine + Nimodipine (Week 8) | 1966.40 |
| Galantamine + Placebo (Week 8) | 2379.83 |
| Galantamine + Nimodipine (Week 24) | 1722.00 |
| Galantamine + Placebo (Week 24) | 3038.81 |
The ADAS-Cog is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation and praxis using an 11-point Assessment Scale. It has a minimum score of 0 and a maximum severity score of 70, and a higher score indicates more impairment. (NCT00814658)
Timeframe: Baseline, Week 8, Week 24
| Intervention | scores on a scale (Mean) |
|---|---|
| Galantamine + Nimodipine (Baseline) | 30.40 |
| Galantamine + Placebo (Baseline) | 28.20 |
| Galantamine + Nimodipine (Week 8) | 25.10 |
| Galantamine + Placebo (Week 8) | 31.03 |
| Galantamine + Nimodipine (Week 24) | 25.02 |
| Galantamine + Placebo (Week 24) | 27.70 |
The NPI evaluates 12 neuropsychiatric domains: delusions, hallucinations, dysphoria, anxiety, aggression, euphoria, dis-inhibition, irritability/lability, apathy, aberrant motor activity, eating disorders, and night-time behavior disturbances. For present domains, the severity and frequency of the behavior are determined. Frequency is rated 1 (rarely) to 4 (very often) and Severity is scored 1 (mild) to 3 (severe). The product scores vary from 1 (mild and rarely) to 12 (very often and severe). Total scores vary from 0 (no present domain) to 144 (all domains are present, are often and severe). (NCT00814658)
Timeframe: Baseline, Week 8, Week 24
| Intervention | scores on a scale (Mean) |
|---|---|
| Galantamine + Nimodipine (Baseline) | 24.0 |
| Galantamine + Placebo (Baseline) | 26.92 |
| Galantamine + Nimodipine (Week 8) | 20.20 |
| Galantamine + Placebo (Week 8) | 22.11 |
| Galantamine + Nimodipine (Week 24) | 15.00 |
| Galantamine + Placebo (Week 24) | 19.75 |
The Quality of Life assessment scale for caregivers of patients with Alzheimer's disease (QoL-AD) is a 13-item scale with four possible scores for each question (score 1: poor and score 4: excellent). It evaluates the caregivers own perceived quality of life. Total score ranges from 13 to 52. Higher scores represent a better outcome. (NCT00814658)
Timeframe: Baseline, Week 8, Week 24
| Intervention | scores on a scale (Mean) |
|---|---|
| Galantamine + Nimodipine (Baseline) | 34.00 |
| Galantamine + Placebo (Baseline) | 36.50 |
| Galantamine + Nimodipine (Week 8) | 32.00 |
| Galantamine + Placebo (Week 8) | 33.56 |
| Galantamine + Nimodipine (Week 24) | 36.60 |
| Galantamine + Placebo (Week 24) | 34.88 |
The Quality of Life assessment scale for patients with Alzheimer's disease (QoL-AD) is a 13-item scale with four possible scores for each question (score 1: poor and score 4: excellent). Total score ranges from 13 to 52. Higher scores represent a better outcome. (NCT00814658)
Timeframe: Baseline, Week 8, Week 24
| Intervention | scores on a scale (Mean) |
|---|---|
| Galantamine + Nimodipine (Baseline) | 33.56 |
| Galantamine + Placebo (Baseline) | 32.67 |
| Galantamine + Nimodipine (Week 8) | 35.60 |
| Galantamine + Placebo (Week 8) | 33.11 |
| Galantamine + Nimodipine (Week 24) | 36.60 |
| Galantamine + Placebo (Week 24) | 33.86 |
The Quality of Life assessment scale for patients with Alzheimer's disease (QoL-AD), according to the opinion of the caregiver is a 13-item scale with four possible scores for each question (score 1: poor and score 4: excellent). It evaluates the opinion of the caregiver about the patient's quality of life. Total score ranges from 13 to 52. Higher scores represent a better outcome. (NCT00814658)
Timeframe: Baseline, Week 8, Week 24
| Intervention | scores on a scale (Mean) |
|---|---|
| Galantamine + Nimodipine (Baseline) | 28.33 |
| Galantamine + Placebo (Baseline) | 29.33 |
| Galantamine + Nimodipine (Week 8) | 27.80 |
| Galantamine + Placebo (Week 8) | 29.78 |
| Galantamine + Nimodipine (Week 24) | 29.80 |
| Galantamine + Placebo (Week 24) | 29.13 |
The Clinical Global Impression (CGI) is a scale to assess treatment response in patients with mental disorders. The Clinical Global Impression Improvement scale (CGI-I) requires the clinician to rate how much the patient's illness has improved or worsened relative to a baseline state. A patient's illness is compared to change over time and rated as: very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. (NCT00814658)
Timeframe: Week 4, Week 8, Week 16, Week 24
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very much improved | Much improved | Minimally improved | No change | Minimally worse | Much worse | Very much worse | |
| Galantamine + Nimodipine (Week 16) | 0 | 1 | 2 | 1 | 1 | 0 | 0 |
| Galantamine + Nimodipine (Week 24) | 0 | 1 | 3 | 1 | 0 | 0 | 0 |
| Galantamine + Nimodipine (Week 4) | 0 | 1 | 1 | 4 | 1 | 0 | 0 |
| Galantamine + Nimodipine (Week 8) | 0 | 0 | 2 | 2 | 1 | 0 | 0 |
| Galantamine + Placebo (Week 16) | 0 | 0 | 3 | 5 | 0 | 0 | 0 |
| Galantamine + Placebo (Week 24) | 0 | 2 | 4 | 1 | 1 | 0 | 0 |
| Galantamine + Placebo (Week 4) | 0 | 1 | 5 | 4 | 0 | 0 | 0 |
| Galantamine + Placebo (Week 8) | 0 | 1 | 6 | 2 | 0 | 0 | 0 |
14 reviews available for nimodipine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
A systematic review of the efficacy of donepezil hydrochloride combined with nimodipine on treating vascular dementia.
Topics: Alzheimer Disease; Dementia, Vascular; Donepezil; Humans; Mental Status and Dementia Tests; Nimodipi | 2022 |
Pharmacotherapy for the treatment of depression in patients with alzheimer's disease: a treatment-resistant depressive disorder.
Topics: Alzheimer Disease; Antipsychotic Agents; Calcium Channel Blockers; Clinical Trials as Topic; Depress | 2018 |
[Positron emission tomography: contribution to diagnosis of dementia and development of disease-modifying drugs].
Topics: Alzheimer Disease; Amyloid; Clinical Trials as Topic; Cohort Studies; Drug Discovery; Early Diagnosi | 2009 |
Nimodipine for primary degenerative, mixed and vascular dementia.
Topics: Alzheimer Disease; Calcium Channel Blockers; Dementia, Vascular; Double-Blind Method; Humans; Nimodi | 2002 |
[Pivotal role of ganglioside in aggregation of amyloid beta-protein].
Topics: Alzheimer Disease; Amyloid beta-Peptides; G(M1) Ganglioside; Genetic Variation; Humans; Membrane Mic | 2004 |
[The importance of nimodipine in treatment of dementia].
Topics: Alzheimer Disease; Animals; Calcium Channel Blockers; Calcium Signaling; Dementia; Dementia, Vascula | 2005 |
Single photon emission computed tomography and positron emission tomography imaging of multi-drug resistant P-glycoprotein--monitoring a transport activity important in cancer, blood-brain barrier function and Alzheimer's disease.
Topics: Alzheimer Disease; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Tran | 2006 |
The calcium rationale in aging and Alzheimer's disease. Evidence from an animal model of normal aging.
Topics: Aging; Alzheimer Disease; Animals; Calcium; Calcium Channel Blockers; Calcium Channels; Hippocampus; | 1994 |
Clinical findings with nimodipine in dementia: test of the calcium hypothesis.
Topics: Alzheimer Disease; Calcium; Calcium Channel Blockers; Controlled Clinical Trials as Topic; Dementia, | 1995 |
Aging, dementia and calcium metabolism.
Topics: Aged; Aging; Alzheimer Disease; Animals; Brain; Calcium; Calcium Channel Blockers; Dementia, Vascula | 1998 |
Nimodipine for primary degenerative, mixed and vascular dementia.
Topics: Alzheimer Disease; Calcium Channel Blockers; Dementia, Vascular; Humans; Nimodipine | 2000 |
Nimodipine for primary degenerative, mixed and vascular dementia.
Topics: Alzheimer Disease; Calcium Channel Blockers; Dementia, Vascular; Double-Blind Method; Humans; Nimodi | 2001 |
Global rating, symptoms, behavior, and cognitive performance as indicators of efficacy in clinical studies with nimodipine in elderly patients with cognitive impairment syndromes.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Attention; Dementia, Multi-Infarct; Humans; Mental Recal | 1992 |
Clinical testing of compounds modifying acute and chronic neurodegeneration in the CNS.
Topics: Aged; Alzheimer Disease; Central Nervous System; Cerebrovascular Disorders; Clinical Trials as Topic | 1990 |
6 trials available for nimodipine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Co | 2014 |
The calcium rationale in aging and Alzheimer's disease. Evidence from an animal model of normal aging.
Topics: Aging; Alzheimer Disease; Animals; Calcium; Calcium Channel Blockers; Calcium Channels; Hippocampus; | 1994 |
Calcium channel blocker nimodipine for primary degenerative dementia.
Topics: Aged; Alzheimer Disease; Follow-Up Studies; Humans; Neuropsychological Tests; Nimodipine | 1991 |
Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia.
Topics: Administration, Oral; Aged; Alzheimer Disease; Dose-Response Relationship, Drug; Double-Blind Method | 1990 |
Nimodipine in the treatment of old age dementias.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Blood Pressure; Dementia; Double-Blind Method; El | 1990 |
Clinical testing of compounds modifying acute and chronic neurodegeneration in the CNS.
Topics: Aged; Alzheimer Disease; Central Nervous System; Cerebrovascular Disorders; Clinical Trials as Topic | 1990 |
20 other studies available for nimodipine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Calcium; Calcium Channels; Cell Prol | 2006 |
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholines | 2009 |
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Butyrylcholinesterase; Calcium; Cel | 2011 |
Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cell Survival; Cholinesterase Inhibi | 2018 |
Polycyclic maleimide-based derivatives as first dual modulators of neuronal calcium channels and GSK-3β for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Calcium Channels, N-Type; Glycogen Synthase Kinase 3 beta; Humans; Maleimides; Po | 2019 |
Oral nimodipine treatment has no effect on amyloid pathology or neuritic dystrophy in the 5XFAD mouse model of amyloidosis.
Topics: Administration, Oral; Alzheimer Disease; Animals; Calcium Channel Blockers; Disease Models, Animal; | 2022 |
Suppression of Selective Voltage-Gated Calcium Channels Alleviates Neuronal Degeneration and Dysfunction through Glutathione S-Transferase-Mediated Oxidative Stress Resistance in a
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Caenorhabditis elegans; Caenorhabditis elegans Pr | 2022 |
Multi-target 1,4-dihydropyridines showing calcium channel blockade and antioxidant capacity for Alzheimer's disease therapy.
Topics: Alzheimer Disease; Antioxidants; Calcium; Calcium Channel Blockers; Calcium Channels; Dihydropyridin | 2019 |
Design, Synthesis and Biological Evaluation of New Antioxidant and Neuroprotective Multitarget Directed Ligands Able to Block Calcium Channels.
Topics: Alzheimer Disease; Antioxidants; Calcium; Calcium Channel Blockers; Calcium Channels; Cell Line, Tum | 2020 |
Calcium channel blockade attenuates abnormal synaptic transmission in the dentate gyrus elicited by entorhinal amyloidopathy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Calcium Channel Blockers; Dentate Gyrus; Entorhin | 2016 |
Convection-enhanced delivery of neprilysin: a novel amyloid-β-degrading therapeutic strategy.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antigens, Nuclear; Calcium Channel Blocker | 2012 |
Nimodipine inhibits IL-1β release stimulated by amyloid β from microglia.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Cell Death; Cell Line; | 2012 |
[Early diagnosis and treatment of Alzheimer's disease. Implementation in the doctor's office].
Topics: Aged; Alzheimer Disease; Brief Psychiatric Rating Scale; Carbamates; Cholinesterase Inhibitors; Dihy | 2002 |
Protective effects of ginsenoside Rg2 against glutamate-induced neurotoxicity in PC12 cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Calcium; Calcium Channel | 2007 |
Amyloid beta-peptide (A beta P) potentiates a nimodipine-sensitive L-type barium conductance in N1E-115 neuroblastoma cells.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Barium Compounds; Cell Line; Chlorides; | 1994 |
[The use of nimodipine in elderly dementia patients].
Topics: Aged; Alzheimer Disease; Calcium Channel Blockers; Dementia, Vascular; Drug Evaluation; Female; Huma | 1995 |
Prescribing practice with cognition enhancers in outpatient care: are there differences regarding type of dementia?--Results of a representative survey in lower Saxony, Germany.
Topics: Adult; Alzheimer Disease; Ambulatory Care; Data Collection; Dementia; Dementia, Vascular; Female; Ge | 1996 |
High-performance liquid chromatography with ultraviolet and fluorimetric detection for the simultaneous determination of tacrine, nimodipine, and their respective metabolites in the plasma of patients with Alzheimer disease.
Topics: Alzheimer Disease; Calibration; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Dru | 1998 |
Clinical results with nimodipine in Alzheimer disease.
Topics: Alzheimer Disease; Animals; Calcium; Calcium Channels; Humans; Nimodipine; Rats; Receptors, Nicotini | 1992 |
[A real advance in therapy for clinical practice].
Topics: Alzheimer Disease; Cerebrovascular Disorders; Humans; Neurocognitive Disorders; Nimodipine | 1990 |